AKBA let's see if we get share price appreciation as we get closer to FDA approval for the blockbuster drug Vadadustat for anemia on
03/29/22 for dialysis patients and more importantly non dialysis patients.! AKBA bulls let's accumulate under $3.00 for a move to $12-15 range after FDA approval for Vadadustat!
(0)
(0)
Akebia Therapeutics Inc. (AKBA) Stock Research Links